Schrödinger, Inc.

Schrödinger, Inc.

Company type	Public
Industry	Scientific software, Biotechnology
Founded	1990
Headquarters	New York City , United States
Area served	Worldwide
Products	Molecular modeling software, Enterprise Informatics Platform LiveDesign

Schrödinger, Inc. operates as an international enterprise specializing in scientific software and biotechnology, focusing on computational solutions tailored for drug discovery and materials science. Its sophisticated platform empowers pharmaceutical companies, biotechnology organizations, and academic researchers to model molecular interactions at the atomic scale, thereby expediting the development of drugs and materials while minimizing both time and expenses.

The company's software portfolio encompasses tools for molecular dynamics simulations, quantum mechanics and free energy computations, as well as virtual screening applications. Additionally, Schrödinger offers consulting expertise and collaborates with prominent industry players to drive forward advancements in computational chemistry and pharmaceutical innovation.

Products and services

Schrödinger’s technology delivers precision comparable to experimental data when forecasting compound attributes such as solubility and binding affinity. Among its primary products are molecular modeling software and the Enterprise Informatics Platform LiveDesign, which facilitates enhanced teamwork among multidisciplinary research groups.

Apart from its software offerings, Schrödinger also creates tailored enterprise solutions, provides educational training, designs high-performance computing clusters, and engages in research-oriented drug discovery initiatives.

Academic organizations have the opportunity to acquire licenses for Schrödinger’s software specifically for educational use and nonprofit research activities.

Partners

The company maintains strategic alliances with major pharmaceutical corporations like Bayer and Takeda, utilizing its computational drug discovery platform to streamline their development processes. Nimbus Therapeutics, co-founded by Schrödinger, applies this platform for drug design efforts. In 2016, Nimbus transferred an Acetyl-CoA carboxylase (ACC) inhibitor developed through Schrödinger’s technology to Gilead Sciences in a transaction valued at up to $1.2 billion. By 2019, this ACC inhibitor progressed into advanced clinical trials targeting non-alcoholic steatohepatitis (NASH), underscoring Schrödinger’s significant role in pharmaceutical progress and market expansion.

Recognition

In 2013, Schrödinger achieved a milestone by executing the largest and fastest cloud computing task globally at that time, deploying 156,000 cores on Amazon Web Services to screen more than 205,000 molecules for materials science applications. This accomplishment followed a 2012 project where Cycle Computing constructed a 50,000-core virtual supercomputer leveraging Schrödinger’s infrastructure to analyze 2.1 million compounds within three hours. These feats highlight the company’s leadership in high-performance computational chemistry and its substantial influence on technological innovation within the sector.